LYSINE BIOTECH PRIVATE LIMITED
A Revolutionary CAR T-Cell Treatment with Global Potential
CIN:U74999TN2018PTC122879
| S.No | 1.PRODUCT 2nd generation of CAR T Cells Therapy | Discovery stage and Early process development | Preclinical | Clinical trials |
| 1 | LB101 Development of Commercial Novel huanti-CAR19T-CD27/41-BB-CD3Z Cells Therapy: Towards Enhanced Efficacy and Safety | 2027 |